SCHEDULE: BlackRock Discloses 4.2% Stake in Candel Therapeutics

BlackRock Inc. has reported a 4.2% beneficial ownership in Candel Therapeutics Inc. as of March 31, 2026, holding over 3 million shares.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Candel Therapeutics Inc. common stock.
• As of March 31, 2026, BlackRock beneficially owned 3,079,861 shares, representing 4.2% of the class.
• The filing specifies that BlackRock has sole voting power over 3,042,067 shares and sole dispositive power over 3,079,861 shares.
• No single person is known to have an interest exceeding five percent of the total outstanding common shares of Candel Therapeutics Inc. in relation to dividends or sale proceeds.
• The filing is an amendment (Amendment No. 1) to a previous filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by a large institutional investor and does not provide new operational or financial information about Candel Therapeutics.

Positives

• BlackRock, a significant institutional investor, has taken a notable stake in Candel Therapeutics, which could be interpreted as a positive signal of confidence in the company's prospects.
• The ownership percentage of 4.2% indicates substantial investment by BlackRock.

Negatives

• The filing does not contain any negative financial results or operational setbacks for Candel Therapeutics.

Risks

• The filing does not explicitly mention any current issues or potential future challenges for Candel Therapeutics.

Future Outlook

The filing itself is a historical disclosure of ownership as of a specific date and does not contain forward-looking statements or guidance from Candel Therapeutics Inc.

Industry Context

StockSavvy.ai notes that the acquisition of a significant stake by a major asset manager like BlackRock in a biotechnology company like Candel Therapeutics often signals potential validation of the company's technology or market position, though it is primarily a reporting requirement for large shareholders.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which may be viewed positively by other shareholders as a sign of confidence, but does not directly impact current share value.
• Management: The filing is a standard disclosure and does not directly impact management's operational responsibilities.
• Creditors: No direct impact on creditors as the filing concerns equity ownership.

Next Steps

• BlackRock will continue to hold its shares in Candel Therapeutics Inc. unless it decides to increase, decrease, or sell its stake.
• Candel Therapeutics Inc. will continue its business operations as disclosed in its other filings.

Key Dates

Keywords

Candel Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment